PIM 447

Drug Profile

PIM 447

Alternative Names: LGH-447; Pan-pim inhibitor - Novartis Oncology; PIM447

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis Oncology
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Australia (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in France (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top